Fosfomycin enhances the active transport of tobramycin in *Pseudomonas aeruginosa*

David L. MacLeod¹*, Jyoti Velayudhan¹, Thomas F. Kenney¹, Joseph H. Therrien¹, Jennifer L. Sutherland¹, Lynn M. Barker¹ and William R. Baker¹

¹Gilead Sciences, Inc., Seattle, Washington 98121, USA

*Corresponding author. Tel: 1-206-728-5090 (ext. 3024); Fax: 1-206-728-5095;
E-mail: Dave.MacLeod@gilead.com.

Running title: Fosfomycin enhances active uptake of tobramycin
ABSTRACT

Elevated levels of mucins present in bronchiectatic airways predispose patients to bacterial infections and reduce the effectiveness of antibiotic therapies by directly inactivating antibiotics. Consequently, new antibiotics that are not inhibited by mucins are needed to treat chronic respiratory infections caused by Pseudomonas aeruginosa and Staphylococcus aureus. In these studies, we demonstrate that fosfomycin synergistically enhances the activity of tobramycin in the presence of mucin. The bactericidal killing of a novel 4:1 (wt/wt) combination of fosfomycin:tobramycin (FTI) is superior (>9-log_{10} CFU/mL) relative to its individual components fosfomycin and tobramycin. Additionally, FTI has a mutation frequency resulting in antibiotic resistance >3-Log_{10} lower than fosfomycin and 4-Log_{10} lower than tobramycin for P. aeruginosa. Mechanistic studies revealed that chemical adducts are not formed, suggesting that the beneficial effects of the combination are not due to molecular modification of the components. FTI displayed time-kill kinetics similar to tobramycin and killed in a concentration-dependent fashion. The bactericidal effect resulted from inhibition of protein biosynthesis rather than cell wall biosynthesis. Studies using radio-labeled antibiotic demonstrated tobramycin uptake was energy-dependent and that fosfomycin enhanced the uptake of tobramycin in P. aeruginosa in a dose-dependent manner. Lastly, mutants resistant to fosfomycin and tobramycin were auxotrophic for specific carbohydrates and amino acids suggesting that the resistance arises from mutations in specific active transport mechanisms. Overall, these data demonstrate that fosfomycin enhances the uptake of tobramycin, resulting in increased inhibition of protein synthesis and ultimately bacterial killing.
The airways of cystic fibrosis (CF) and non-CF bronchiectasis patients are restricted by sputum, a thick viscous secretion containing elevated levels of mucin, DNA from inflammatory cells, filamentous actin (F-actin), lipids and peptides (8, 17, 25, 48). The altered biophysical properties of sputum impair mucociliary clearance resulting in airway obstructions and predispose the patients to bacterial infections (48). Whole sputum (19, 44) and individual components of sputum, including mucin, DNA and F-actin bundles also reduce the activity of cationic antibiotics and peptides (7, 43) thereby contributing to development of bacterial resistance (30, 33). Furthermore, microscopic analysis of sputum from CF patients demonstrates that *P. aeruginosa* grows in aggregations or microcolonies and exhibit decreased susceptibility to tobramycin due to production of biofilms (4, 27, 54). Development of antibiotic resistance is clearly a concern for patients with bronchiectasis. New antibiotic therapies with improved activity in the lung environment are needed to treat chronic airway infections.

FTI is an antibiotic combination consisting of a 4:1 (wt/wt) ratio of fosfomycin and tobramycin (29). It has broad spectrum *in vitro* activity against both Gram-negative and Gram-positive bacterial pathogens commonly found in CF and non-CF bronchiectasis patients, including methicillin-resistant *Staphylococcus aureus* (MRSA). FTI is also highly active *in vivo*. In a chronic rat lung infection model with *P. aeruginosa*, BID aerosol treatment with FTI achieved complete eradication of the infection (>6-Log_{10} CFU/lung) after 3 days. Furthermore, the *in vivo* studies demonstrated that FTI had >1 Log_{10} killing relative to the component weights of fosfomycin and tobramycin, and confirmed the enhanced antibacterial activities of FTI observed
in the present in vitro study. Together, these data suggest that FTI may be an appropriate aerosol antibiotic therapy for CF and non-CF bronchiectasis patients.

Inhalation of nebulized solutions of antibiotics delivers high concentrations of drug directly to the site of infection. However, the physiology of normal and diseased lung inhibits antibiotic activity thus reducing the effectiveness of the therapy. Standardized methods for evaluating antibiotics are often not predictive of drug activity in the lung environment. Mucin, which is present in large quantities in bronchietatic airways, has been used as an in vitro tool to study the bioavailability of antibiotics and to evaluate the mucolytic activity of expectorants (11, 49, 63).

We used mucin as an in vitro model of airway sputum to provide additional insights for evaluating activities of antibiotics in the lung environment. Purified porcine gastric mucin (PGM) was used as the source of mucin in this research because it has a similar glycoprotein-carbohydrate composition as airway mucus, namely high levels of MUC5AC and MUC5b (24, 42). Additionally, we have used this model to optimize various fosfomycin:aminoglycoside combinations eventually leading to the selection of the 4:1 (wt/wt) ratio of fosfomycin:tobramycin currently in Phase II clinical trials.

Our studies demonstrated that fosfomycin, the major component of FTI, enhanced the activity of tobramycin against P. aeruginosa in mucin and significantly reduced the development of antibiotic resistance. Mechanistic studies revealed that the enhancement arose from increased uptake of tobramycin, resulting in increased inhibition of protein synthesis and bactericidal killing. These data strongly suggest that the improved killing kinetics of FTI will minimize development of clinical antibiotic resistance. Lastly, our studies suggested that tobramycin is
transported into *P. aeruginosa* by active transport systems designed to transport specific carbohydrates and amino acids (28).
MATERIALS AND METHODS

Bacterial strains and antibiotics

P. aeruginosa ATCC 27853 and S. aureus ATCC 29213 (The America Type Culture Collection, Manassas, VA) were used in antibiotic susceptibility, single step resistance and mechanistic studies. P. aeruginosa PAO-1 parent strain and PAO-1 ISlacZ/hah or ISphoA/hah transposon mutants (PA0427, PA2018, PA2019, PA2020, PA2291, PA3186 and PA5235) were obtained from Colin Manoil, University of Washington, Seattle, WA (20). Fosfomycin disodium and tobramycin sulfate were obtained from Sigma-Aldrich (St. Louis, MO). FTI consisted of a 4:1 ratio (wt/wt basis) of fosfomycin and tobramycin. Glucose-6-phosphate (Sigma-Aldrich) was added to the bacteriological culture media at a final concentration of 25 µg/mL for all evaluations of fosfomycin and FTI (23, 24), but not tobramycin. The enantiomer of fosfomycin, (+)-(1S,2R)-epoxypropylphosphonic acid disodium salt (Cy-230), was synthesized by a modification of Glamkowski (1970) incorporating a crystallization step with (-)-α-phenethylamine to isolate the desired isomer (16).

FTI susceptibility studies

MICs were determined according to CLSI standards or by a modified agar plate-dilution method (36, 37) that incorporated 20 g/L of purified porcine gastric mucin (PGM; Sigma-Aldrich) in Mueller Hinton agar (MHA;BBL, Sparks, MD). The MIC was defined as the lowest concentration of antibiotic that prevented visible growth after incubation at 35°C for 18-24 h.
Time-kill experiments were performed according to a modified CLSI method (38). Antibiotics were evaluated alone and in combination at multiples of the MIC in cation-adjusted Mueller Hinton Broth (CAMHB) (Remel; Lenexa, KS, USA) containing 20 g/L PGM. Bacterial cultures and antibiotic(s) were incubated at 37°C in a shaking water bath (200 rpm) and viability assessed by the plate count method at 0, 1, 2, 4, 6 and 24 h. A no-drug control was run in each assay. Antibiotics that reduced the original inoculum by ≥3-log \(_{10}\) were considered bactericidal. Antibiotics that reduced the original inoculum by ≤2-log \(_{10}\) were considered bacteriostatic.

**Single-step resistance to FTI**

Development of resistance after a single exposure to antibiotic was determined for *P. aeruginosa* ATCC 27853. Late Log-phase cultures containing 10\(^9\)-10\(^{10}\) CFU were spread onto Mueller Hinton Agar (BBL; Sparks, MD) plates containing 20g/L PGM and 4X, 8X or 16X the MIC of FTI, fosfomycin or tobramycin. The culture plates were incubated at 35°C for 48 h and the number of colonies on each plate was enumerated manually. The frequency of resistance was calculated by dividing the number of bacteria growing at the defined antibiotic concentration by the number of bacteria in the inoculum (30).

**Fosfomycin:tobramycin chemical adducts**

FTI (512 µg/mL) was prepared in phosphate-buffered saline (PBS, pH 7.4) and incubated for 24 h at room temperature (rt), 37°C or 89°C. An Agilent 1100 Series HPLC system equipped with an LC/MSD Ion Trap Mass Spectrometer and ChemStation data acquisition/data analysis software (Agilent Technologies; Santa Clara, CA) was used to detect potential chemical adducts.
of fosfomycin and tobramycin. Peak separation was effected using a Symmetryshield RP18 analytical column, 4.6 mm i.d. x 150 mm length, with 3.5 µm packing (Waters Corporation; Milford, MA). The samples were eluted with 5% glacial acetic acid and 0.25% pentafluoropropionic acid (PFPA) in water as mobile phase A, and 5% glacial acetic acid and 0.25% PFPA in acetonitrile as mobile phase B. An elution gradient was applied from 0% to 34% mobile phase B over 25 minutes. Peaks were eluted directly from the column into the electrospray ionization source of the ion trap mass spectrometer. Ionization was in positive mode, using nitrogen as a drying gas at 10 L/min and 350 °C. Mass spectra were acquired over a range of 150 to 1300 m/z. Antibacterial activities of FTI incubated at room temperature, 37°C or 89 °C were evaluated by MIC.

Inhibition of protein and cell wall biosynthesis

Protein and cell wall peptidoglycan biosynthesis were determined by measuring the incorporation of a tritiated (³H) L-amino acid mixture (Ala, Arg, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro, Ser, Thr, Tyr, Val; GE Healthcare Bio-Sciences Corp.; Picataway, NJ; catalog no. TRK440; 1.8 TBq/mmol) and N-acetyl-D-glucosamine [³H] NAG (GE Healthcare Bio-Sciences; catalog no. TRK376; 296 GBq/mmol), respectively (3, 51). An overnight culture of *P. aeruginosa* ATCC 27853 was diluted 1:1000 in 50 mL CAMHB + 20 g/L PGM in a 125 mL Erlenmeyer flask and incubated at 37°C, with shaking (200 rpm) for 1.5 h. Two milliliters of early log phase cultures (~2 x 10⁷ CFU/mL) were pulsed with 10 µCi of ³H-aa (1.93 GBq/milliatom carbon) or 10 µCi of [³H] NAG (296 GBq/mmol) for 1 h at 37°C, 200 rpm. FTI, fosfomycin, or tobramycin were then added to cultures and incubated as described above for up to an additional 4 h. At various time points, 100 µl aliquots (triplicate) of culture were removed
and macromolecules precipitated with 10% TCA (VWR). All samples were treated identically to reduce variation in quenching. Precipitates were harvested onto glass fiber filters (GFC) (PerkinElmer; Waltham, MA), washed two times with 35 mL of normal saline to remove unincorporated isotope followed by one wash with 35 mL of 90% ethanol (VWR). Counts per minute (CPM) were determined using a Wallac MicroBeta Trilux (PerkinElmer).

**Tobramycin uptake**

Antibiotic uptake was determined by measuring incorporation of [³H] tobramycin (540 mCi/mmol, Moravek Biochemicals; Brea, CA). An overnight culture of *P. aeruginosa* ATCC 27853 was diluted in nutrient broth (NB) (Difco & BBL; Sparks, MD) to an OD₆₂₅ of 0.013 and incubated at 37°C with shaking (250 rpm) until it reached an OD₆₂₅ of ~0.5. Cells were harvested by centrifugation (6000 x g, room temperature, 5 min), washed once in NB and re-suspended in pre-warmed NB to an OD₆₂₅ of 0.25. Unlabelled fosfomycin was added 0, 0.05, 0.1, 1, 10, and 100 µg/mL and the cultures incubated for 3 min at 37°C with shaking (250 rpm). [³H] tobramycin (2.3 µg/mL) was added to each tube and the cultures were incubated at 37°C with shaking (250 rpm) for an additional 2 min. Five milliliter volumes were filtered through 0.45 µm nitrocellulose membrane filters (Whatman Inc., Florham Park, NJ), pre-soaked with 410 mM MgCl₂ (VWR), and cpm determined with a MicroBeta scintillation counter. All samples were treated identically to reduce variation in quenching. The effect of electron transport uncouplers and divalent cations on [³H] TOB uptake was determined by incorporating 1 mM sodium cyanide (Sigma-Aldrich) or 1 mM MgCl₂ (Sigma Aldrich) into the NB 3 min prior to addition of [³H] tobramycin as described above.
Late Log-phase cultures (10⁹-10¹⁰ CFU) of P. aeruginosa ATCC 27853 and PAO-1 were spread onto Mueller Hinton Agar (BBL; Sparks, MD) plates containing 4X, 8X or 16X the MIC of FTI, fosfomycin or tobramycin (1, 3, 5, 38). The culture plates were incubated at 37°C for 48 h and individual colonies purified by streaking to isolation. MIC values of representative mutants were compared to the parent strains to confirm increases in MIC. Spontaneous mutants having decreased susceptibility to fosfomycin and tobramycin were evaluated for their ability to utilize a variety of carbohydrates and amino acids as sole carbon and nitrogen sources (1, 3, 5, 26, 38).

Single colonies were inoculated into normal saline and adjusted to 1 x 10⁸ CFU/mL. Suspensions (1 x 10⁴ CFU) were replica plated using a 48-pin replica plater (Sigma-Aldrich) onto M9 (Becton Dickinson and Company, Sparks, MD) agar plates supplemented with MgSO₄ (2 mM), CaCl₂ (0.1 mM) and 5 g/L carbohydrate or 5 g/L amino acid. Plates were incubated at 37°C for 48 h and growth assessed visually. Carbohydrates: Fru, D-fructose; Glc, D-glucose; G3P, sn-glycerol-3-phosphate; Gly, glycerol; Mtl, D-mannitol; NAG, N-acetyl-D-glucosamine; Rib, D-ribose; Suc, succinate; G6P, D-glucose-6-phosphate; F6P, D-fructose-6-phosphate; Spm, spermidine; Put, Putrescine. L-amino acids: Ala, alanine; Gly, glycine; Pro, proline; Trp, tryptophan, Asn, asparagine; Gln, glutamine; Asp, asparagine; Glu, glutamate; Lys, lysine; Arg, arginine; His, histidine.
RESULTS

FTI susceptibility studies

We studied the effects of mucin, a major component of normal airway mucus and sputum, on the antibacterial activities of a novel fosfomycin:tobramycin combination because mucin is known to reduce the effectiveness of cationic antibiotics used to treat respiratory infections in CF and non-CF bronchiectasis patients (31, 44). Time-kill experiments conducted in the presence of mucin demonstrated that both FTI and tobramycin were rapidly bactericidal and exhibited concentration-dependent killing against *P. aeruginosa*. Increasing the concentrations of FTI and tobramycin increased both the rate and extent of bacterial killing (Fig. 1a & Fig. 1b). By comparison, fosfomycin was bacteriostatic for *P. aeruginosa* and demonstrated time-dependent killing (Fig. 1c).

The activity of FTI relative to its component weights of fosfomycin and tobramycin against *P. aeruginosa* ATCC 27853 is shown in Fig. 2a. At 4X MIC (16 μg/mL), the killing activity of FTI was superior (>9-Log_{10} CFU) relative its components fosfomycin (12.8 μg/mL) and tobramycin (3.2 μg/mL). FTI rapidly reached bactericidal killing (1-2 h), while tobramycin and fosfomycin alone exhibited bacteriostatic killing. Additionally, FTI remained bactericidal at 24 h, while regrowth of the bacterial culture was observed with tobramycin and fosfomycin. A 4:1 (wt/wt) fosfomycin enantiomer (Cy-230):tobramycin combination did not demonstrate enhanced killing relative to its components (Fig. 2c). FTI also demonstrated improved activity relative to fosfomycin and tobramycin against *S. aureus* ATCC 29213 (Fig. 2b).
Table 1 shows the spontaneous mutation frequencies of *P. aeruginosa* ATCC 27853 after a single exposure to antibiotic in the presence of mucin. At 16X the MIC, the mutation frequency in the presence of FTI was $\geq 3\text{-Log}_{10}$ lower than for fosfomycin alone and 4-$\text{Log}_{10}$ lower than for tobramycin alone. FTI remained superior to fosfomycin at 8X the MIC, but comparable fosfomycin and tobramycin at 4X the MIC. Tobramycin at 4X and 8X the MIC resulted in confluent lawns.

**Fosfomycin; tobramycin chemical adducts**

The chemical structures of fosfomycin, tobramycin and five possible adducts are presented in Suppl. Fig. 1. No chemical adducts were detected by HPLC/MS after incubation of FTI at rt or 37°C for 24 h (Suppl., Fig. 2). Three adducts were formed after incubation at 89°C for 24 h, and the activity of the resulting mixture against *P. aeruginosa* ATCC 27853 had a 2-fold increase in MIC relative to FTI. Since the three adducts were positional isomers and isobaric, their exact identities were not determined. Incubation of FTI at -20°C, rt or 37°C did not alter antimicrobial activity.

**Inhibition of macromolecular biosynthesis**

The effects of antibiotic concentration and time of bacterial exposure to antibiotic on protein and cell wall biosynthesis were determined by measuring the uptake of $^3$H-aa and [$^3$H] NAG, respectively. FTI inhibited protein and cell wall biosynthesis to a greater degree than either fosfomycin or tobramycin. Inhibition of protein synthesis by FTI was dose-dependent, like that of tobramycin, and occurred at concentrations close to the MIC. Increasing the concentration of FTI also resulted in increased inhibition of cell wall biosynthesis; however, protein biosynthesis
was inhibited to a greater degree than cell wall biosynthesis (Table 2). By comparison, increasing the concentration of fosfomycin did not result in increased inhibition of either protein or cell wall biosynthesis. Time-response studies also demonstrated that FTI was acting primarily through inhibition of protein synthesis (Fig. 3a) and correlated well with the onset of bactericidal activity in time-kill studies (Fig. 1a). The inhibition of protein synthesis by FTI at 8 µg/mL was rapid (time to 50% inhibition, T_{50%} = 108 min) compared to 6.4 µg/mL fosfomycin (T_{50%} = 145 min) and 1.6 µg/mL tobramycin (T_{50%} > 180 min). Tobramycin had less activity on its target, protein synthesis, than fosfomycin. This is likely due to the inhibitory action of mucin as well as the concentration of tobramycin used in this experiment. In contrast, FTI (8 µg/mL) caused a more gradual inhibition of cell wall biosynthesis (T_{50%} = 152 min), while neither fosfomycin (6.4 µg/mL) nor tobramycin (1.6 µg/mL) reached 50% inhibition within 180 min (Fig. 3b).

**Tobramycin uptake**

[^3]H] tobramycin uptake in *P. aeruginosa* was characterized by determining the effects of: (i) time of incubation of antibiotic and bacteria; (ii) antibiotic concentration, (iii) incubation temperature; (iv) electron transport uncouplers; (iv) divalent cations. Uptake of[^3]H] tobramycin occurred rapidly and in a time- (Fig. 4a) and concentration-dependent fashion (Fig. 4b). The rate and degree of tobramycin uptake decreased with incubation temperature (Fig. 4c). When *P. aeruginosa* was incubated with 1 mM NaCN,[^3]H] tobramycin transport was inhibited, demonstrating an energy-dependent transport mechanism (Fig. 4d). Furthermore,[^3]H] tobramycin uptake was inhibited by the divalent cation Mg^{2+} (Fig. 4e). Fosfomycin increased the uptake of[^3]H] tobramycin in *P. aeruginosa* in a dose-dependent manner (Fig. 5). Addition
of 10µg/mL fosfomycin resulted in a 170% increase in [3H] tobramycin uptake relative to the no-fosfomycin control.

Carbon and nitrogen auxotrophies of fosfomycin and tobramycin resistant mutants

The *P. aeruginosa* PAO-1 parent strain was able to utilize a wide variety of carbohydrates (Table 3) and L-amino acids (Table 4) as sole carbon and nitrogen sources. Two different classes of tobramycin resistant mutants were identified in this study. C400 was able to utilize glucose, succinate and putrescine, but was auxotrophic to fructose, glycerol-3-phosphate, glycerol, mannitol, N-acetyl-D-glucosamine, ribose, glucose-6-phosphate, fructose-6-phosphate and spermidine. C401 was auxotrophic to fructose, glucose-6-phosphate, N-acetyl-D-glucosamine and spermidine. Two classes of fosfomycin isolates were also identified and referred to as C398 and C399. C398 was broadly auxotrophic, while C399 was auxotrophic to glycerol-3-phosphate, maltose and ribose. Auxotrophies for amino acids are also shown in Table 4. Both C400 and C401 were unable to utilize tryptophan, while C400 was also auxotrophic for glycine, lysine, arginine and histidine. C398 was broadly auxotrophic while C399 displayed utilization patterns identical to the parent strain PAO-1.

Characterization of transport mutants

To gain further insights into potential transport systems identified from the carbohydrate and amino acid auxotrophy studies, we characterized select PAO-1 mutants with transposon insertions in genes encoding glucose porins, efflux transporters and a glycerol-3-phosphate transporter (Table 5). Both the oprB and the glucose-sensitive porin mutants showed a 2-fold
increase in tobramycin MIC relative to the parent PAO-1 strain. In time-kill experiments, tobramycin (1 µg/mL) prevented growth of the oprB mutant, but resulted in 3 Log10 killing of PAO-1 at 4 h (Fig. 6.) The oprB mutant was auxotrophic for glycerol (Table 5). Mutations in efflux transporter genes mexX, mexY and oprM resulted in a 2-4 fold decrease in tobramycin MIC, while the mexZ mutant had a 2-fold increase in MIC. Uptake of [3H] tobramycin in the mexZ mutant was not significantly different from the PAO-1 parent strain (Fig. 7.) and none of the efflux transporter mutants had carbohydrate or amino acid auxotrophies. Mutation of the glpT gene resulted in high levels of fosfomycin resistance and a glycerol-3-phosphate auxotrophy, but no change in tobramycin susceptibility (Table 5). Time-kill studies demonstrated that killing of P. aeruginosa with fosfomycin (4 µg/mL)) is not enhanced by addition of glucose-6-phosphate to the CAMHB (Fig. 8.).
DISCUSSION

We demonstrate here that fosfomycin enhances the activity of tobramycin in the presence of mucin by increasing active uptake of tobramycin resulting in greater inhibition of protein synthesis. In contrast, tobramycin alone had greatly reduced antibacterial activity in the presence of mucin. This finding was in agreement with that of Mendelman et al. who reported that 16X tobramycin MIC was required for bactericidal killing of *P. aeruginosa* in CF sputum (31). Antibiotic activity in the lung microenvironment is of particular concern in the management of CF and non-CF bronchiectasis patients (45). Current inhaled therapies deliver high concentrations of antibiotic to the airways but rarely eradicate the infections (15, 62). Repeated exposure to antibiotics combined with sub-optimal reductions of bacterial CFU’s lead to selection of antibiotic resistant bacterial populations (33, 34). *P. aeruginosa* and *S. aureus* isolates, particularly those from CF patients, are resistant to many of the currently approved antibiotics (12, 32, 50). Consequently, existing antibiotic monotherapies are becoming less effective for treating bacterial infections because of increasing resistance.

In this study, experiments comparing the rate and degree of killing of FTI to the component weights of fosfomycin and tobramycin show that fosfomycin enhances the activity of tobramycin 9-Log_{10} CFU/mL against *P. aeruginosa* and *S. aureus*. Identical experiments incorporating the enantiomer of fosfomycin in combination with tobramycin did not show a similar enhancement, suggesting that the absolute stereochemistry of fosfomycin and/or biological activity are required to reduce the inhibitory effects of mucin on tobramycin. Previous studies have shown that fosfomycin enhances the time-kill kinetics of gentamicin (47) and amikacin (46) against methicillin-resistant *S. aureus* and *P. aeruginosa* 59957 RyC, respectively. Here we demonstrate...
the utility of the phenomenon for the enhancement of tobramycin activity by fosfomycin in the
presence of mucin. The high antibacterial activity of FTI in mucin was also reflected in
resistance studies. The spontaneous mutations resulting in resistance after a single exposure to
FTI was 3-4 Log_{10} lower than those of fosfomycin and tobramycin alone and decreased with
increasing drug concentration. By comparison, tobramycin had a very high SMF even at 16X
MIC. Previous reports have shown that *P. aeruginosa* biofilms grown on mucin-coated surfaces
develop large cellular aggregates and have increased tolerance to tobramycin (27). Our
susceptibility data demonstrate that fosfomycin enhances the antibacterial activities of
tobramycin in mucin, resulting in bactericidal killing and thus reducing the development of
resistance.

The molecular mechanism by which fosfomycin enhances the activity of tobramycin is
unknown. It is possible that adducts formed between tobramycin and fosfomycin could possess
improved antibacterial activity. Aminoglycosides and some β-lactams chemically interact when
combined to form new chemical entities via nucleophilic cleavage of the β-lactam ring by one of
the amino groups of tobramycin (18). Based on the number of primary amines on tobramycin,
formation of at least five adducts with fosfomycin is possible. However, no chemical adducts of
fosfomycin and tobramycin were detected by HPLC/MS after incubation of FTI at rt or 37°C for
24 h. This suggests the enhanced antibacterial activities were not due to new chemical entities.
Furthermore, the three adducts formed at 89°C had 2-fold lower activity than FTI incubated at rt
or 37°C.
It is also plausible that when fosfomycin and tobramycin are combined at a 4:1 (wt/wt) ratio, uptake of one or both of the antibiotics into the bacterial cell is enhanced, resulting in improved activity. The major component of FTI, fosfomycin, is a phosphonic acid derivative that inhibits the first step of peptidoglycan biosynthesis in the bacterial cell wall by irreversibly binding to the enzyme phosphoenoxypruvate (UDP-N-acetylglucosamine enolpyruval-transferase) (22). The minor component, tobramycin, prevents protein biosynthesis by causing translational errors and by inhibiting translocation (56, 61). Based on these well-characterized mechanisms of action, we provide several lines of evidence that strongly suggest the enhanced activities of FTI are due to increased uptake of tobramycin rather than fosfomycin: (i) time-kill curves demonstrated that both FTI and tobramycin were bactericidal and killed in a concentration-dependent fashion while fosfomycin was bacteriostatic and killed in a time-dependent fashion; (ii) macromolecular biosynthesis studies showed that FTI and tobramycin inhibited protein synthesis in a concentration-dependent fashion; (iii) FTI inhibited protein synthesis faster and to a greater degree than cell wall biosynthesis at a concentration (8 µg/ml) and in a time-frame (2-4 h) that corresponded to bactericidal killing; (iv) addition of 10 µg/mL fosfomycin resulted in a 170% increase in [³H] tobramycin uptake relative to the no-fosfomycin control.

The higher levels of cell associated tobramycin could be explained by passive uptake due to a compromised cell wall, increased facilitated diffusion across the outer membrane via a porin or increased active uptake across the cytoplasmic membrane through a carrier mediated transport system. Alternatively, increased accumulation of tobramycin could be due to impaired efflux. The concentration of fosfomycin used in our studies had little effect on cell wall biosynthesis, rendering the first of these possibilities unlikely. To probe for explanations associated with
transport phenomena, fosfomycin and tobramycin resistant mutants were generated and their ability to grow on single carbon sources examined. Two classes of tobramycin resistant mutants each with distinct carbohydrate utilization patterns were identified in this study. Mutant C400 was unable to utilize fructose, glycerol and mannitol as sole carbon sources. The *P. aeruginosa* porin OprB is known to facilitate the diffusion of glucose, glycerol, fructose and mannitol (64-65) and uptake of these sugars is inducible (41). Consistent with our findings, Bryan *et al.* (1981) demonstrated that a streptomycin-resistant *P. aeruginosa* mutant generated by transposon mutagenesis was unable to transport glucose and glycerol and suggested this was due to functional loss of OprB (6). In our investigations, demonstrated that oprB (PA3186) and a glucose-sensitive porin (PA2291) mutant had two-fold increases in tobramycin MIC suggesting a possible role in transporting tobramycin across the outer membrane of *P. aeruginosa*. Decreased susceptibility to tobramycin was confirmed for the oprB mutant in time-kill experiments. Auxotrophies of these mutants were not fully characterized, but the oprB mutant was auxotrophic for glycerol. This data is consistent with previous reports showing that glycerol is transported into *P. aeruginosa* by OprB (64). Since glycerol uptake is inducible (64) and since fosfomycin is also a substrate for glycerol transporters (9,22), fosfomycin may be inducing uptake of tobramycin via OprB. However, C400 had a 16-fold increase in tobramycin MIC, compared to a 2-fold increase for the oprB mutant. This suggests the high level of tobramycin resistance in C400 is due to multiple independent mutations.

Since both fosfomycin and tobramycin have cytoplasmic targets, it is also possible that tobramycin enters the cytoplasm of *P. aeruginosa* through active transport systems normally used for transporting carbohydrates or amino acids (1, 40), and that fosfomycin enhances this
uptake. Interestingly, C400 was also auxotrophic for hexose-6-phosphate sugars (G6P & F6P) and G3P which are transported into *E. coli* and *S. aureus* by two phosphoenopyruvate:sugar phosphotransferase systems (PTS); the uptake of hexose-6-phosphate (UhpT) and glycerol-3-phosphate (GlpT) transport, respectively. Fosfomycin is also transported into *E. coli* and *S. aureus* via GlpT and UhpT, and mutation of these transporters results in fosfomycin resistance and auxotrophies for their respective substrates. *P. aeruginosa* contains the GlpT transport system (52,53), but the UhpT transport system appears to be absent (9). As a result, uptake and susceptibility to fosfomycin is not increased by addition of G6P to bacteriological culture media as the case with *E. coli* (22). Interestingly, the closest homolog to UhpT in *P. aeruginosa* is GlpT (9). We also demonstrated in this study that a *glpT* transposon mutant (PA5235) had a 16-fold increase in fosfomycin MIC, severely impaired growth on G3P, but no auxotrophies for either G6P or F6P. The tobramycin MIC of the *glpT* mutant was unchanged, demonstrating that the G6P and F6P auxotrophies and tobramycin resistance of C400 were not the result of a mutation in *glpT*.

The tobramycin resistant mutant C401 was auxotrophic for G3P, NAG and Fru suggesting a distinct mutation(s) from C400. NAG and Fru are actively transported into *P. aeruginosa* by the phosphotransferase system (21). Amino sugars like NAG are used for synthesis of the peptidoglycan component of the bacterial cell wall, the target of fosfomycin (22, 26). It’s possible that fosfomycin causes stimulation of cell wall biosynthesis genes and induces uptake of tobramycin due to its structural similarity to NAG. Tobramycin consists of two aminoglucose molecules covalently linked to a 2-deoxystreptamine nucleus (61). The aminoglucose moieties have structural similarity to NAG and D-glucose, (41, 55).
In P. aeruginosa, arginine is actively transported by multiple systems including the basic-amino-acid specific porin OprD (21, 57,58). Furthermore, Arginine has been shown to increase tobramycin susceptibility in P. aeruginosa grown under anaerobic growth conditions (5). C400 was also auxotrophic for arginine, but we have not further evaluated known arginine transport mutants. Tamber et al., (2006) demonstrated that mutation of oprD and 18 homologues in P. aeruginosa did not alter tobramycin susceptibilities (58). However, MICs were determined under aerobic conditions and their role in tobramycin resistance may have been underestimated. It is plausible that fosfomycin is inducing a broad substrate transport system(s) normally expressed only in the presence of arginine and under micro-aerophillic or anaerobic conditions and that tobramycin is actively transported across the cytoplasmic membrane.

The fosfomycin resistant mutant C398 was pan auxotrophic for carbohydrates and amino acids. In E. coli, transport of carbohydrates requires the cyclic AMP receptor protein (cAMP-CRP) complex (2, 60). Mutation of genes in this complex leads to fosfomycin resistance and broad carbohydrate auxotrophies (1,2,10,60). It is possible that C398 may have mutations in the cyclic AMP receptor protein (CRP). The second fosfomycin resistant mutant C399 was auxotrophic for G3P, Mtl and ribose, but did not have any amino acid auxotrophies.

The MexXY-oprM efflux system is a major aminoglycoside resistance mechanism in P. aeruginosa (14). Since active uptake and efflux are both energy-dependent, it is also plausible that fosfomycin inhibits tobramycin efflux resulting in increased accumulation of tobramycin. In this study we developed several lines of evidence that strongly demonstrate that fosfomycin is not inhibiting tobramycin efflux: (i) time-course studies demonstrated that fosfomycin induced a
rapid accumulation of [3H] tobramycin within 5 min, while [3H] tobramycin efflux was not evident until 30-60 min; (ii) mexX, mexY, oprM and mexZ mutants had 2-fold changes in tobramycin MICs relative to the wild-type parent PAO-1 strain, but no changes in fosfomycin MICs. If fosfomycin was inhibiting tobramycin efflux via MexXY-OprM, we would expect that mutation of these genes would also cause changes in fosfomycin MIC; (iii) despite >20 years of clinical usage of fosfomycin in treating urinary tract infections caused by Gram-negative bacteria, fosfomycin resistant efflux mutants have not been reported. The major fosfomycin resistance mechanisms in clinical isolates are due to mutation of cya, ptsI, glpT and uhpT genes or to the presence of FosA (39); (iv) MexZ, a negative regulator of MexXY-OprM, is the most frequent clinically derived efflux mutation resulting in aminoglycoside resistance in P. aeruginosa isolates from CF patients (14, 35). In this study, a mexZ mutant had a 2-fold increase in tobramycin MIC, but it did not show a decrease in [3H] tobramycin uptake as would be expected with activation of MexXY-OprM efflux. This data also strongly demonstrates that tobramycin efflux is not the underlying mechanism; (v) mexY and mexZ mutants did not have auxotrophies for either carbohydrates or amino acids demonstrating a different resistance mechanism than the spontaneous mutants isolated in this study; (vi) the characteristics of [3H] tobramycin uptake was similar to that of active transport of carbohydrates and amino acids in P. aeruginosa (13, 23, 59). Specifically, we observed an approximate five-fold change in tobramycin uptake in 5-10 min, tobramycin uptake was inducible with fosfomycin, tobramycin uptake was concentration dependent over 0.3-2.3 µg/mL. Saturation was not achieved because concentrations of tobramycin >4 µg/mL are rapidly bactericidal for P. aeruginosa. Tobramycin uptake was also temperature dependent and rates decreased from 37°C to 25 °C. Lastly, tobramycin uptake was energy dependent and could be inhibited with sodium azide. Taken
together, these data strongly demonstrate that fosfomycin is inducing the active uptake of tobramycin rather than inhibiting tobramycin efflux.

The objective of this study was to gain insights into the synergistic activity of a novel 4:1 fosfomycin:tobramycin combination in the presence of mucin. We have demonstrated for the first time that fosfomycin enhances the active transport of tobramycin in *P. aeruginosa*. In our model, increased levels of tobramycin reaching the target results in greater inhibition of protein synthesis, greater bacterial killing and ultimately a lower frequency of resistance. Furthermore, we provide good insights into the systems that transport tobramycin across the outer and cytoplasmic membranes. It is unclear from the present studies whether fosfomycin and tobramycin share the same transport system, or if fosfomycin is inducing tobramycin uptake via coordinate regulation of a different transport system. Additional studies utilizing a variety of molecular approaches are warranted to conclusively identify the genes involved in the activation and transport of tobramycin. Lastly, while the present study focused primarily on *P. aeruginosa*, we have also shown that FTI has enhanced activity against *S. aureus*. Both *P. aeruginosa* and *S. aureus* are known to transport and metabolize many of the same carbohydrates and amino acids, and also share transport systems for fosfomycin. Therefore, it is plausible that fosfomycin is also inducing tobramycin uptake in *S. aureus* via the same mechanism.
ACKNOWLEDGEMENTS

This study was supported by Gilead Sciences, Inc. Portions of the data were presented at the American Thoracic Society, May 16-21, 2008, Toronto, Ontario, Canada (abstract C64) and the 22nd Annual North American Cystic Fibrosis Conference, October 23-25, 2008, Orlando, Florida (abstract 350). We thank Robert Mourey and Will Watkins for critical review of the manuscript.

REFERENCES


FIGURE LEGENDS

FIG. 1. Time-kill curves for *P. aeruginosa* 27853 showing concentration-dependent killing by (a) FTI and (b) tobramycin and time-dependent killing by (c) fosfomycin. Antibiotics were evaluated at multiples of the MIC in CAMHB supplemented with 2 g/L of PGM.

FIG. 2. Fosfomycin enhanced the killing of tobramycin against (a) *P. aeruginosa* ATCC 27853 and (b) *S. aureus* ATCC 29213, relative to the component weights of fosfomycin and tobramycin. The fosfomycin enantiomer CY-230 + tobramycin combination did not demonstrate enhanced killing relative to its components against (c) *P. aeruginosa*. Time-kill curves were conducted in CAMHB supplemented with 2 g/L of PGM. Antibiotics were tested at the following concentrations: fosfomycin, 12.8 µg/mL plus tobramycin, 3.2 µg/mL (open square); fosfomycin, 12.8 µg/mL (closed circle); tobramycin, 3.2 µg/mL (closed triangle); fosfomycin enantiomer Cy-230, 12.8 µg/mL plus tobramycin, 3.2 µg/mL (open triangle); and cy-230, 12.8 µg/mL (open circle); no drug (closed square); bactericidal killing (dotted line).

FIG. 3. Time-response studies demonstrating that FTI acts primarily through inhibition of protein synthesis. The inhibitory effects of FTI and the component weights of fosfomycin and tobramycin on (a) protein and (b) cell wall biosynthesis in *P. aeruginosa* ATCC 27853 grown in CAMHB supplemented with 2 g/L of PGM. FTI, 8 µg/mL (closed circle); tobramycin, 1.6 µg/mL (closed triangle); and fosfomycin, 6.4 µg/mL (closed square). Values represent the mean ± SD of four independent experiments.
FIG. 4. Active transport characteristics of \([^3]H\) tobramycin (2.3 µg/mL) in \(P. aeruginosa\) PAO-1. (a) accumulation occurred in a rapid, time-dependent fashion, (b) uptake at 5 min was concentration-dependent, (c) accumulation over 5 min was temperature-dependent; cultures grown at 37\(^\circ\)C (closed triangle) versus 25\(^\circ\)C (closed square), (d) the electron transport inhibitor NaCN (1 mM) blocked uptake demonstrating energy dependence, and (e) uptake was inhibited by the divalent cation MgCl\(_2\) (1 mM).

FIG. 5. Fosfomycin induces uptake of \([^3]H\) tobramycin (2.3 µg/mL) in \(P. aeruginosa\) ATCC 27853 in a dose-dependent fashion. Incorporation of \([^3]H\) tobramycin into bacterial cells was determined 5 min after addition of unlabelled fosfomycin (0, 0.05, 0.1, 1, 10, or 100 µg/mL). Values represent the mean ± SD of four independent experiments. Statistical differences were evaluated by the Student’s t-test (*P<0.05, **P<0.005).

FIG. 6. Time-kill curves demonstrating that a \(P. aeruginosa\) PAO-1 oprB mutant (closed circle) was less susceptible to 1 µg/mL tobramycin than the PAO-1 parent strain (closed triangle). No drug controls were included for both the PAO-1 parent (open triangle) and PAO-1 oprB mutant (open circle).

FIG. 7. Inactivation of mexZ, the transcriptional regulator of mexXY efflux transport system does not alter \([^3]H\) tobramycin uptake. \(P. aeruginosa\) PAO-1 parent strain and the mexZ mutant PA2020 were incubated with 2.3 µg/mL \([^3]H\) tobramycin for 30 min. Values represent the mean ± SD of seven independent experiments. Statistical differences were evaluated by the Student’s t-test (ns; P=0.689).
FIG. 8. Time-kill curves of *P. aeruginosa* 27853 demonstrating that addition of 0.1-1000 µg/mL of glucose-6-phosphate (G6P) to CAMHB does not improve killing by fosfomycin (4 µg/ml).
<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Mucin MIC (µg/mL)</th>
<th>Fold MIC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>4x</td>
</tr>
<tr>
<td>FTI</td>
<td>4</td>
<td>5 x 10^{-6}</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>4</td>
<td>7 x 10^{-6}</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>0.5</td>
<td>TNTC</td>
</tr>
</tbody>
</table>

TNTC: To numerous to count.
### TABLE 2. Effects of antibiotic concentration on protein and cell wall synthesis in *P. aeruginosa* ATCC 27853.

<table>
<thead>
<tr>
<th>Antibiotic Concentration (µg/mL)</th>
<th>% Inhibition*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Protein</td>
</tr>
<tr>
<td>FTI (16)</td>
<td>92</td>
</tr>
<tr>
<td>FTI (8)</td>
<td>50</td>
</tr>
<tr>
<td>FTI (4)</td>
<td>28</td>
</tr>
<tr>
<td>Fosfomycin (12.8)</td>
<td>9</td>
</tr>
<tr>
<td>Fosfomycin (6.4)</td>
<td>21</td>
</tr>
<tr>
<td>Fosfomycin (3.2)</td>
<td>0</td>
</tr>
<tr>
<td>Tobramycin (3.2)</td>
<td>42</td>
</tr>
<tr>
<td>Tobramycin (1.6)</td>
<td>6</td>
</tr>
<tr>
<td>Tobramycin (0.8)</td>
<td>2</td>
</tr>
</tbody>
</table>

* % inhibition at 2h relative to the no-drug control
TABLE 3. Growth properties of tobramycin or fosfomycin resistant mutants of *P. aeruginosa* PAO-1 on carbohydrates and polyamines.

<table>
<thead>
<tr>
<th>Strain</th>
<th>MIC (µg/mL)</th>
<th>Fru</th>
<th>G1c</th>
<th>G3P</th>
<th>Gly</th>
<th>Mlt</th>
<th>NAG</th>
<th>Rib</th>
<th>Suc</th>
<th>G6P</th>
<th>F6P</th>
<th>Spm</th>
<th>Put</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAO-1</td>
<td>0.5</td>
<td>128</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>C400</td>
<td>8</td>
<td>128</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>C401</td>
<td>8</td>
<td>128</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>C398</td>
<td>0.5</td>
<td>4096</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>C399</td>
<td>0.5</td>
<td>512</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

FOF=fosfomycin; TOB=tobramycin
TABLE 4. Growth properties of tobramycin and fosfomycin resistant mutants of *P. aeruginosa* PAO-1 on L-amino acids.

<table>
<thead>
<tr>
<th>Strain</th>
<th>MIC (µg/mL)</th>
<th>FOF</th>
<th>TOB</th>
<th>Ala</th>
<th>Gly</th>
<th>Pro</th>
<th>Trp</th>
<th>Asn</th>
<th>gln</th>
<th>Asp</th>
<th>Glu</th>
<th>Lys</th>
<th>Arg</th>
<th>His</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAO-1</td>
<td>0.5 128</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C400</td>
<td>8 128</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C401</td>
<td>8 128</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C398</td>
<td>0.5 4096</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C399</td>
<td>0.5 512</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FOF=fosfomycin; TOB=tobramycin
Table 5. Characteristics of *P. aeruginosa* PAO-1 transposon mutants.

<table>
<thead>
<tr>
<th>Mutant ORF</th>
<th>Gene</th>
<th>Description</th>
<th>MIC (µg/mL)</th>
<th>Carbohydrate &amp; Amino Acid Auxotrophies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>TOB</td>
<td>FOF</td>
</tr>
<tr>
<td>PAO-1</td>
<td></td>
<td>Parent strain, burn wound</td>
<td>0.5</td>
<td>128</td>
</tr>
<tr>
<td>PA2291</td>
<td></td>
<td>Glucose-sensitive porin</td>
<td>1.0</td>
<td>128</td>
</tr>
<tr>
<td>PA3186</td>
<td>oprB</td>
<td>Outer membrane porin OprB precursor</td>
<td>1.0</td>
<td>128</td>
</tr>
<tr>
<td>PA0427</td>
<td>oprM</td>
<td>Outer membrane protein OprM precursor</td>
<td>0.125</td>
<td>128</td>
</tr>
<tr>
<td>PA2018</td>
<td>mexY</td>
<td>RND efflux membrane fusion protein</td>
<td>0.25</td>
<td>128</td>
</tr>
<tr>
<td>PA2019</td>
<td>mexX</td>
<td>RND multidrug efflux transporter</td>
<td>0.25</td>
<td>128</td>
</tr>
<tr>
<td>PA2020</td>
<td>mexZ</td>
<td>Transcriptional regulator</td>
<td>1.0</td>
<td>128</td>
</tr>
<tr>
<td>PA5235</td>
<td>glpT</td>
<td>Glycerol-3-phosphate transporter</td>
<td>0.5</td>
<td>4096</td>
</tr>
</tbody>
</table>

ND= Not determined; FOF=fosfomycin; TOB=tobramycin
FIG. 1a.

![Graph showing bacterial growth and drug concentrations](image)

FIG. 1b.

![Graph showing bacterial growth and drug concentrations](image)

FIG. 1c.

![Graph showing bacterial growth and drug concentrations](image)
FIG. 2a. Bactericidal activity of FOF, TOB, and FTI against bacteria. The graphs show the Log10 CFU/mL of bacteria over time (h) for different concentrations of FOF (12.8 µg/mL), TOB (3.2 µg/mL), and FTI (16 µg/mL).

FIG. 2b. Bactericidal activity of TOB and Cy-230. The graphs show the Log10 CFU/mL of bacteria over time (h) for TOB (3.2 µg/mL) and Cy-230 (12.8 µg/mL) alone and in combination.

FIG. 2c. Bactericidal activity of TOB, Cy-230, and TOB + Cy-230. The graphs show the Log10 CFU/mL of bacteria over time (h) for TOB (3.2 µg/mL), Cy-230 (12.8 µg/mL), and TOB (3.2 µg/mL) + Cy-230 (12.8 µg/mL).
FIG. 4a.

FIG. 4b.
FIG. 4c.

![Graph showing Time (min) vs. CPM (x 10^5)]

FIG. 4d.

![Bar chart showing CPM (x 10^4) for (-) NaCN and (+) NaCN treatments]
FIG. 4e

![Graph showing CPM (x 10^5) with treatments (-) MgCl2 and (+) MgCl2.](image)

FIG. 5.

![Graph showing CPM (x 10^5) with varying Fosfomycin concentrations.](image)
FIG. 6.

![Graph showing CFU/mL over hours.](attachment:image6.png)

FIG. 7.

![Bar chart showing CPM (x 10^5) for WT and mexZ.](attachment:image7.png)
FIG. 8.

- Bactericidal Line
- No Drug
- 0
- 0.1 µg/mL
- 1 µg/mL
- 10 µg/mL
- 100 µg/mL
- 1000 µg/mL

Log$_{10}$ CFU/mL vs. Time (h)